#268: Two Undervalued Stocks to Add to Your Portfolio
Anne Marie and Mike are back and they are here to pitch two big name stocks trading on the cheap. First up: Novo Nordisk. The Ozempic darling soared in 2024, but tough competition from Eli Lilly and a tumultuous relationship with Hims & Hers has left this pharmaceutical in the bin. Mike goes over its latest troubles…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Stock Club
See all episodes →Chapters Group: Europe's Mini Constellation Software With Compounding Quality's Pieter Slegers
Ouster & Schaeffler: Two More Investicon Stock Picks, One Year Later | Stock Club 323
Two Overlooked AI Stocks Worth Knowing About
Similar episodes from other shows
More like Stock Club →
Amazon Up, Walgreens, Nike & McPlant Down
Tradeable Lows, Nvidia’s Data Center Finance Deal, Surprise Comebacks for Schwab and Expedia
Can a GLP-1 Pill Revive Novo Nordisk?
Your Q4 Market Playbook, and the Odds for Sports Betting Stocks
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.